Keros Therapeutics, Inc.
KROS
$18.10
$1.277.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37,798.31% | 85,820.30% | 91,657.69% | 2,250.99% | 8,037.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37,798.31% | 85,820.30% | 91,657.69% | 2,250.99% | 8,037.50% |
| Cost of Revenue | -4.91% | 24.38% | 29.25% | 28.37% | 34.95% |
| Gross Profit | 154.21% | 130.49% | 121.54% | -25.88% | -34.43% |
| SG&A Expenses | 16.78% | 18.02% | 9.58% | 16.99% | 19.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.76% | 23.08% | 25.16% | 26.04% | 31.67% |
| Operating Income | 121.36% | 100.17% | 94.26% | -24.06% | -31.26% |
| Income Before Tax | 139.18% | 116.00% | 109.08% | -22.26% | -27.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 135.50% | 111.17% | 102.63% | -22.46% | -27.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 135.50% | 111.17% | 102.63% | -22.46% | -27.45% |
| EBIT | 121.36% | 100.17% | 94.26% | -24.06% | -31.26% |
| EBITDA | 122.19% | 100.89% | 94.95% | -23.93% | -31.11% |
| EPS Basic | 130.43% | 106.91% | 97.21% | 3.52% | -5.26% |
| Normalized Basic EPS | 133.60% | 110.82% | 102.17% | 3.66% | -5.27% |
| EPS Diluted | 129.54% | 104.78% | 97.15% | 23.14% | 17.00% |
| Normalized Diluted EPS | 132.75% | 109.96% | 101.32% | 3.66% | -5.27% |
| Average Basic Shares Outstanding | 16.22% | 20.91% | 23.59% | 27.13% | 21.34% |
| Average Diluted Shares Outstanding | 16.55% | 21.26% | 23.96% | 27.13% | 21.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |